Drug Development Unit

Aim: To explore, generate, and validate new combinatorial pharmacotherapies aimed at improving different aspects of the metabolic syndrome.

  • Design, synthesize, and explore the metabolic benefits of novel peptide hormone and nuclear hormone combinations;
  • Assess the preclinical efficacy of new multi-agonists at the GLP-1, GIP, and glucagon receptors;
  • Explore new pathways that mimic the metabolic benefits of cold exposure and assess their druggability.

We use cookies to improve your experience on our Website. We need cookies to continually improve our services, enable certain features, and when we embed third-party services or content, such as the Vimeo video player or Twitter feeds. In such cases, information may also be transferred to third parties. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.